Systemic lupus erythematosus in Asturias, Spain: clinical and serologic features - PubMed (original) (raw)

Systemic lupus erythematosus in Asturias, Spain: clinical and serologic features

Jesús Gómez et al. Medicine (Baltimore). 2006 May.

Free article

Abstract

Asturias is an autonomous region in the north of Spain with historical and anthropologic peculiarities. In the current report, we examine the main clinical and immunologic features of 363 patients with systemic lupus erythematosus (SLE), virtually the entire population of SLE patients in Asturias. We constructed a database with the clinical and immunologic features of all patients fulfilling the American College of Rheumatology criteria, based on the review of hospital records corresponding to blood samples received for antinuclear antibodies testing since 1992. Arthritis was the most frequently observed main clinical feature and neuropathy was the rarest. Male patients had a disease more frequently characterized by serositis (p<0.05) and neurologic disorder (p<0.01) than females, while children presented malar rash (p<0.05), fever (p<0.05), and kidney involvement (p<0.01) more often than adults. Late-onset patients were characterized by lower frequencies of malar rash (p<0.01), neurologic disorder (p<0.05), alopecia (p<0.01), and lymphadenopathy (p<0.05) than young adults. Numerous direct and inverse significant associations were found among clinical and immunologic features. The most relevant significant associations were neurologic disorder with lupus anticoagulant (p<0.01); kidney involvement with serositis (p<0.01) and DNA antibodies (p<0.05); and thrombosis with DNA antibodies (p<0.05), cardiolipin antibodies (p<0.01), and lupus anticoagulant (p<0.01). A low mortality was found in our series, although kidney involvement (p<0.05) and cardiolipin antibodies (p<0.05) are factors associated with poor survival.

PubMed Disclaimer

References

    1. Abusamieh M, Ash J. Atherosclerosis and systemic lupus erythematosus. Cardiol Rev. 2004;12:267-275.
    1. Beaufils M, Kouki F, Mignon F, Camus JP, Morel-Maroger L, Richet G. Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. Am J Med. 1983;74:201-205.
    1. Boddaert J, Huong du LT, Amoura Z, Wechsler B, Godeau P, Piette JC. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 2004;83:348-359.
    1. Borchers AT, Keen CL, Schoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3:423-453.
    1. Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Sherwin R, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz DW, Hebel JR, Kittner SJ. Antiphospholipid antibodies and stroke in young women. Stroke. 2002;33:2396-2400.

Publication types

MeSH terms

Substances

LinkOut - more resources